dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.contributor.author | Gemici, Aliihsan | |
dc.contributor.author | Usta, Furkan Selim | |
dc.contributor.author | Çakır, Aslı | |
dc.contributor.author | Sadri, Sevil | |
dc.contributor.author | Bekoz, Hüseyin | |
dc.contributor.author | Sargın, Fatma Deniz | |
dc.date.accessioned | 2022-04-05T09:39:38Z | |
dc.date.available | 2022-04-05T09:39:38Z | |
dc.date.issued | 2019 | en_US |
dc.identifier.citation | Sevindik, Ö. G., Gemici, A., Usta, F. S., Çakır, A., Sadri, S., Bekoz, H. ... Sargın, F. D. (2019). Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO). 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). Orlando Florida, December 7-10, 2019. https://dx.doi.org/10.1182/blood-2019-126195 | en_US |
dc.identifier.issn | 0006-4971 | |
dc.identifier.issn | 1528-0020 | |
dc.identifier.uri | https://dx.doi.org/10.1182/blood-2019-126195 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/9218 | |
dc.description.abstract | Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. Despite growing evidence regarding its efficacy and safety among AML patients there is limited data about the use of GO in isolated extra-medullary relapsed AML. Extramedullary AML remains as an unmet clinical need regarding the poor prognosis and lack of a standard therapeutic approach. Our cases demonstrated a rapid and long lasting response with a favorable toxicity profile, in patients who were treated with GO as a single agent after an isolated extramedullary relapsing disease. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | The American Society of Hematology | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Acute Myeloid Leukemia (AML) | en_US |
dc.subject | Gemtuzumab Ozogamycin (GO) | en_US |
dc.subject | Stem Cell Transplantation | en_US |
dc.title | Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO) | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 134 | en_US |
dc.identifier.issue | Supplement:1 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1182/blood-2019-126195 | en_US |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.institutionauthor | Gemici, Aliihsan | |
dc.institutionauthor | Usta, Furkan Selim | |
dc.institutionauthor | Çakır, Aslı | |
dc.institutionauthor | Bekoz, Hüseyin | |
dc.institutionauthor | Sargın, Fatma Deniz | |